Paul Tudor Jones's TVTX Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 5,955 shares of Travere Therapeutics, Inc. (TVTX) worth $338,304, representing 0.00% of the portfolio. First purchased in 2021-Q2, this long-term strategic position has been held for 21 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in TVTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 120,165 shares. Largest reduction occurred in Q3 2025, reducing 105,761 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Travere Therapeutics (TVTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Travere Therapeutics (TVTX) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -27,406 | Reduce 82.15% | 5,955 | $56.81 |
| Q1 2026 | -28,825 | Reduce 46.35% | 33,361 | $29.71 |
| Q4 2025 | -33,561 | Reduce 35.05% | 62,186 | $38.21 |
| Q3 2025 | -105,761 | Reduce 52.48% | 95,747 | $23.90 |
| Q2 2025 | +38,130 | Add 23.34% | 201,508 | $14.80 |
| Q1 2025 | +120,165 | Add 278.08% | 163,378 | $17.92 |
| Q4 2024 | +5,069 | Add 13.29% | 43,213 | $17.42 |
| Q3 2024 | +861 | Add 2.31% | 38,144 | $13.99 |
| Q2 2024 | -103 | Reduce 0.28% | 37,283 | $8.22 |
| Q1 2024 | +37,386 | New Buy | 37,386 | $7.71 |
| Q4 2023 | -47,195 | Sold Out | 0 | $0.00 |
| Q3 2023 | -6,047 | Reduce 11.36% | 47,195 | $8.94 |
| Q2 2023 | -13,528 | Reduce 20.26% | 53,242 | $15.36 |
| Q1 2023 | +39,766 | Add 147.26% | 66,770 | $0.02 |
| Q4 2022 | -4,908 | Reduce 15.38% | 27,004 | $0.02 |
| Q3 2022 | +31,912 | New Buy | 31,912 | $24.63 |
| Q2 2022 | -83,437 | Sold Out | 0 | $0.00 |
| Q1 2022 | +20,928 | Add 33.48% | 83,437 | $25.77 |
| Q4 2021 | +5,757 | Add 10.14% | 62,509 | $31.04 |
| Q3 2021 | -23,315 | Reduce 29.12% | 56,752 | $24.25 |
| Q2 2021 | +80,067 | New Buy | 80,067 | $14.59 |
Paul Tudor Jones's Travere Therapeutics Investment FAQs
Paul Tudor Jones first purchased Travere Therapeutics, Inc. (TVTX) in Q2 2021, acquiring 80,067 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Travere Therapeutics, Inc. (TVTX) for 21 quarters since Q2 2021.
Paul Tudor Jones's largest addition to Travere Therapeutics, Inc. (TVTX) was in Q1 2025, adding 163,378 shares worth $2.93 M.
According to the latest 13F filing for Q2 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 5,955 shares of Travere Therapeutics, Inc. (TVTX), valued at approximately $338,304.
As of the Q2 2026 filing, Travere Therapeutics, Inc. (TVTX) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Travere Therapeutics, Inc. (TVTX) was 201,508 shares, as reported at the end of Q2 2025.